{"disease":{"id":"high-risk-smoldering-multiple-myeloma","name":"high risk smoldering multiple myeloma"},"drugs":{"marketed":[{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"High-Risk Smoldering Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"High-Risk Smoldering Multiple Myeloma as monotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07393282","title":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":270,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT01484275","title":"A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT04775550","title":"DARA RVD For High Risk SMM","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61,"lead_sponsor_name":"Omar Nadeem, MD","has_results":false},{"nct_id":"NCT05469893","title":"Immuno-PRISM (PRecision Intervention Smoldering Myeloma)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Irene Ghobrial, MD","has_results":false},{"nct_id":"NCT06745687","title":"BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06574126","title":"Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"PETHEMA Foundation","has_results":false},{"nct_id":"NCT02943473","title":"Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":true}],"total":7},"guidelines":[{"drug_id":"daratumumab","guideline_body":"FDA label","recommendation":"DARZALEX FASPRO as monotherapy in high-risk smoldering multiple myeloma.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}